GlassScriptPhysician profile
Kioumarce Yazdani
NPI 1104810175
$553.69
in general payments reported to CMS, 2019-2025
14 companies · $19.60 in 2025
The $19.60 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $89.61 · 2021: $27.12 · 2022: $13.89 · 2024: $50.07 · 2025: $19.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $69.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $69.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $139.30 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $74.19 | 2019-2020 | |
| Amgen INC. | $62.17 | 2019-2020 | |
| Novo Nordisk INC | $58.62 | 2019-2024 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $36.14 | 2019 | |
| Sanofi Pasteur INC. | $30.62 | 2019-2020 | |
| Pfizer INC. | $29.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.75 | 2022-2024 | Airsupra |
| Corcept Therapeutics | $19.60 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $18.37 | 2020 | |
| Allergan, INC. | $15.96 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.52 | 2019 | |
| Lilly USA, LLC | $14.28 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kioumarce Yazdani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.